



aspurus[®]
MOST INNOVATIVE SHATAVARI

Award Wining
Recognized by Industry experts



Gold standard Clinically studied ingredient
on 70 menopausal women (peri and post)
aged between 40- 65 years for eight weeks.

Dose 500 mg

Product Benefits

- ▶ 85% showed a reduction in hot flashes in as few as 4 weeks.
- ▶ 60% improvement in feelings of fatigue associated with menopause compared to placebo
- ▶ Improvement in vaginal dryness after 8 weeks

Patent-Pending
Extraction process- ensuring to
≤ 5% Shatavarins,
by HPTLC method

Aspurus is a full spectrum extract of Shatavari (*Asparagus racemosus*) root, standardized to ≤ 5% Shatavarins, by HPTLC method. Clinically studied to help in reducing menopausal symptoms aspurus is developed with our patent-pending, clean label technology extraction process, assuring the availability of both major and minor active phyto-constituents.

SUPPORTS TO
REDUCE MORE
THAN
**7 MENOPAUSAL
SYMPTOMS**

▶ Hot Flashes

▶ Night Sweats

▶ Menopausal Stress

▶ Sleeplessness

▶ Fatigue

▶ Irritability

▶ Bladder weakness

▶ Vaginal Dryness

▶ Improves QOL

SUPPORTS IN
NORMALIZATION
OF **HORMONAL
BALANCE**

The herb Shatavari is widely recognized in Ayurveda for its supportive role in female reproductive health through every stage of their life. Shatavari contains steroidal saponins known as Shatavarins which are its primary bioactive constituents.

Study Outcomes:

▶ The Pre-menopausal/menopausal symptoms including vasomotor, psychosocial, physical, and sexual domains were assessed using the total and domain scores of the Utian Quality of Life (UQoL) scale. The results were promising and the intervention group showed significantly better results than the placebo group.

▶ The psychological and behavioral symptoms of Negative Mood, Neverousness, and Stress were assessed using the DASS-21 scale. Significant improvement was observed in the intervention group compared to the placebo.




Figure : Quality of Life evaluation outcome of aspurus[®] (ACTIVE) and placebo at the baseline, day 30, and day 60 using Utian total Quality of Life(QoL).



Figure : Outcome of Negative Mood, Neverousness, and stress evaluation of aspurus[®] and placebo at the baseline, day 30, and day 60 using DASS-21 scores.




Figure : Sleep quality improvement and Insomnia reduction results for aspurus[®] and placebo groups at the baseline, day 30, and day 60 using the RIS scale.

▶ The menopausal symptoms status was assessed using the 5-point Likert Scale during the visit at baseline, day 30, and day 60. The results were significantly better in the intervention group compared to the placebo group.

▶ Hormonal level estimation showed change in the mean serum levels of estradiol and progesterone at day 60 as compared to baseline. Hence, the hormonal balancing effect was tolerable and was within the mean value ranges of estradiol and progesterone.

Waleria is a women owned company focused on bringing in a women's economy power while improving women's health every day. We are pioneering in the realm of Women's Health, founded upon the steadfast pillars of science and research, continually transforming to reveal solutions deeply anchored in the ageless wisdom of traditional Ayurvedic knowledge.

WALERIA

Researching for Ingredients focused on improving women's health

Awfis Tech Park, Ground floor, Plot no 13, Survey 64/2, (New) Software Units Layout Madhapur,HITEC City, Hyderabad, Telangana 500081

Email : info@waleriahealthtech.com | www.aspurushatavari.com

Disclaimer: The information contained in this publication is provided in good faith and is based on our current knowledge. No legally binding promises or warranty regarding the suitability of our product for any specific use is made. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Waleria Healthtech will not assume any expressed or implied liability in connection with any use of this information.